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a  b  s  t  r  a  c  t
Aims:  Cardio-pulmonary  resuscitation  and  therapeutic  hypothermia  (TH)  have  improved  the  neurological
outcomes  of patients  who  have  suffered  sudden  cardiac  arrest;  however,  the  beneﬁts  of  and  differences
between  cooling  devices  remain  unclear.  The  aim of this  study  was  to  clarify  the  signiﬁcance  of  the Arctic
Sun® for surface  cooling  in patients  treated  with  TH.
Methods: Fifty-one  patients  (60.2  ± 14.2  years,  42  males  and 9 females)  who  experienced  cardiogenic
cardiac  arrest,  including  both  shockable  and  non-shockable  cardiac  arrest,  were  enrolled  in this  study.
Forty  patients  were  treated  with  TH  using  the Arctic  Sun  2000® for  surface  cooling,  while  the  other
11  patients  were treated  with  TH  using  conventional  standard  cooling  blankets.  The patients’  clinical
courses  during  TH  and  the  neurological  outcomes  were  compared  between  the  two  groups.
Results: The  body  temperature  before  TH  was  not  signiﬁcantly  different  between  the  two  groups;
however,  the  minimal  body  temperature  during  TH  was  signiﬁcantly  lower  in the  patients  cooled
with  conventional  standard  blankets  than  in  those  cooled  using  the  Arctic  Sun  2000®.  The  rates  of
catecholamine  administration,  left  ventricular  ejection  fraction,  and  mechanical  support  were  not  sig-
niﬁcantly  different  between  the  two  groups;  however,  the  maximum  infusion  dose  of dobutamine  was
signiﬁcantly  lower  in  the patients  with  the  Arctic  Sun  2000® than  in  those  treated  with  standard  cooling
blankets.
Conclusions:  The  use  of  TH with  the  Arctic  Sun  2000® following  cardiac  arrest  is safe  and  effective  in
precisely  maintaining  the target  body  temperature,  and can  be  used  to reduce  the  infusion  dose  of
dobutamine  to  treat  heart  failure  during  TH.
©  2013  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Providing systematic post-cardiac arrest care following the
eturn of spontaneous circulation (ROSC) is very important for
mproving the prognosis of cardiac arrest patients [1]. Therapeu-
ic hypothermia (TH), in particular, became a major method for
reating consciousness disturbance following cardiac arrest after
wo randomized clinical trials were published in 2002 [2,3]. The
merican Heart Association guidelines recommend that comatose
dult patients with ROSC after out-of-hospital ventricular ﬁbril-
ation (VF) cardiac arrest be cooled to 32 ◦C to 34 ◦C for 12 or
4 h (Class I) [1]. Induced hypothermia also may  be considered in
omatose adult patients with ROSC after in-hospital cardiac arrest
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ttp://dx.doi.org/10.1016/j.jjcc.2013.06.013of any initial rhythm or after out-of-hospital cardiac arrest with
an initial rhythm of pulseless electrical activity (PEA) or asystole
(Class IIb) [1]. There are several methods for inducing hypothermia
and maintaining the target body temperature during TH. Infu-
sion of ice-cold ﬂuid, surface cooling, and gastric lavage with
ice-cold water are standard methods for performing TH. Surface
cooling with conventional standard cooling blankets, in particu-
lar, is a readily available and effective method, although it requires
more labor and closer monitoring due to difﬁculties in maintain-
ing the target body temperature. In addition to these methods,
surface cooling devices (Arctic Sun 2000®, Medivance Incorpo-
rated, Louisville, CO, USA) have been used for TH in place of
conventional standard cooling blankets. The Arctic Sun 2000® is a
noninvasive surface cooling device with self-adhesive, hydrogel-
coated pads. The Arctic Sun 2000® has a precise temperature
feedback-control mechanism that can be used to induce rapid cool-
ing to a target body temperature and maintain this temperature
during TH.
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This study investigated the clinical efﬁcacy of Arctic Sun 2000®
ompared with conventional standard cooling blankets as a surface
ooling device.
ethods
This  study was performed in accordance with the ethical stan-
ards of the Declaration of Helsinki, and the Institutional Ethics
eview Board (Ethics Review Board of Chiba Hokusoh Hospital,
ippon Medical School) approved the study protocol (approval
umber 304). All data were retrospectively collected from the med-
cal records. Therefore, written informed consent was  not required
y the ethics review board, and the concept of the study was  dis-
losed on a poster in the institute. There was no ﬁnancial support
or this study, and there are no conﬂicts of interest to declare.
tudy  patients
We  performed TH for patients transported to the emergency
oom (ER) and admitted to the intensive care unit (ICU) follow-
ng cardiac arrest if they met  the inclusion criteria for TH after
cquiring the ROSC (Fig. 1). All patients who received TH with sur-
ace cooling (conventional standard cooling blanket or Arctic Sun
000®) between January 2008 and October 2012 were enrolled in
his study. Cardiac arrest patients who did not meet the inclusion
riteria or who met  exclusion criteria for TH after the ROSC did
ot receive TH and were excluded from this study. Patients who
eceived TH without surface cooling were also excluded from this
tudy.
The initial documented electrocardiogram ﬁndings of cardiac
rrest included ventricular ﬁbrillation (VF), ventricular tachycardia
VT), PEA, and asystole. In all patients, cardiopulmonary resuscita-
ion (CPR) with basic life support and advanced cardiovascular life
upport was performed in accordance with the 2005 and 2010 CPR
uidelines [4–6]. Patients were excluded when time course of car-
iac arrest or the CPR procedures were not clear in the medical
ecords. Coronary artery angiography was performed if ischemic
eart disease was suspected to be the cause of the cardiac arrest.
ardiac diseases were diagnosed on electrocardiography, cardiac
ltrasonography, and coronary artery angiography. Percutaneous
oronary intervention was performed, if coronary artery stenosis
ausing cardiac arrest was present. Intra-aortic balloon pumping
Inclu sion crit eri a fo r thera peutic  hypothermia 
1) Age o ver 1 5 years  old
2) Cardi ogenic c ardiac  arrest
3) Success ful  res uscitati on ( the presence  of  ROSC)
4) Unconsci ousnes s after  ROSC
5) Informed consent from the patient`s family
6) Syst olic blo od press ure ≥ 90mmHg or Mean  blo od pressure ≥ 60mmHg
Exclu sion crit eri a fo r thera peutic  hypothermia
1) Pregnancy
2) Dru g intoxicati on
3) Bleedin g ( or  bleeding t endenc y )
4) Low dail y acti vit y before  cardiac  ar rest 
5) Uncontrollable arrhythmia
ig. 1. Inclusion and exclusion criteria for therapeutic hypothermia. ROSC, return
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(IABP) and percutaneous cardiopulmonary support (PCPS) were
administered to stabilize the hemodynamics of the cardiac arrest
patients. Continuous hemodiaﬁltration (CHDF) was performed,
when a patient required renal replacement therapy to maintain the
homeostasis of the electrolyte and acid–base balance due to renal
failure after the ROSC.
Therapeutic  hypothermia
All  comatose patients were intubated for mechanical ventilation
after achieving ROSC. The comatose patients received TH, if they
met the inclusion criteria (Fig. 1). Sedatives (midazolam or propo-
fol), analgesics (fentanyl), and muscle relaxants (vecuronium) were
administered to patients treated with mechanical ventilation and
TH. TH was initiated using a combination of cooling methods in
the ER or ICU to achieve a target body temperature of 34 ◦C. The
cooling methods included infusion of ice-cold ﬂuids (30 ml/kg),
gastric lavage with ice-cold water, and surface cooling. Surface
cooling was  performed using conventional standard cooling blan-
kets (MEDI-THERM II, Gaymar Industries Incorporated, Orchard
Park, NY, USA) or the Arctic Sun 2000®. After the patient’s body
temperature reached 34 ◦C, it was maintained at 34 ◦C for 24 h
using conventional standard cooling blankets or the Arctic Sun
2000®. The patient’s core temperature was  monitored using a blad-
der catheter thermometer. IABP, PCPS, and CHDF were continued
if necessary during TH. In this study, PCPS and CHDF were not
used to induce TH and maintain the body temperature during TH.
Therefore, the body temperature was  maintained by surface cooling
(conventional standard cooling blanket or Arctic Sun 2000®) also
in patients treated using PCPS or CHDF. Antiarrhythmic drugs (e.g.
amiodarone, nifekalant) were used during TH, if incessant VT or VF
was observed. If patient’s blood pressure fell during TH, dopamine
and/or noradrenaline were administered appropriately to maintain
a systolic blood pressure of ≥90 mmHg  or a mean arterial pressure
of ≥65 mmHg  [1]. Dobutamine was administered appropriately, if
the patient suffered from heart failure with pulmonary congestion
during TH. The infusion dose of dobutamine for heart failure was
gradually increased by the ICU physician until improvement in the
heart failure was observed based on the urine volume, pulmonary
congestion on chest X-ray, oxygenation, and central venous pres-
sure. If the lactate level increased due to insufﬁcient circulation in
spite of sufﬁcient ﬂuid administration during TH, dobutamine was
also administered.
After the patient’s body temperature was  maintained at 34 ◦C for
24 h, rewarming was  performed until the core temperature reached
36 ◦C at a rewarming speed of 1 ◦C per day. After the body temper-
ature was  rewarmed to 36 ◦C, the sedatives and muscle relaxants
were discontinued to verify the patient’s consciousness level.
Clinical  ﬁndings
Age,  gender, medical history, the presence of bystander CPR, the
drug(s) administered for resuscitation, the initial cardiac rhythm,
the underlying disease(s), the body temperature, the blood pres-
sure, and the left ventricular ejection fraction (LVEF) were assessed
before TH. The time course, changes in body temperature, and use
of catecholamines or mechanical support (IABP, PCPS, CHDF) were
also evaluated during TH.
Complications during THPneumonia and bleeding were assessed as complications dur-
ing TH. Pneumonia was  diagnosed based on the ﬁnding on chest
X-ray, the presence of leukocytosis and an increased serum level
of C-reactive protein. If a patient suffered from bleeding during TH



































All (n = 51) Arctic Sun®




Age (years) 60.2 ± 14.2 59.3 ± 15.4 63.5 ± 8.1 0.622
Male (%) 42 (82.4) 33 (82.5) 9 (81.8) 1.000
Medical history (%)
Diabetes  12 (23.5) 10 (25.0) 2 (18.2) 1.000
Hypertension 18 (35.3) 15 (37.5) 3 (27.3) 0.726
Dyslipidemia 15 (29.4) 10  (25.0) 5 (45.5) 0.264
CKD  8 (15.7) 5  (12.5) 3 (27.3) 0.346
Bystander CPR (%) 32 (62.7) 26 (65.0) 6 (54.5) 0.726
Drug administration (%)
Adrenaline  23 (45.0) 17 (42.5) 6 (54.5) 0.514
Amiodarone 8 (15.7) 6 (15.0) 2 (18.2) 1.000
Onset to ROSC
(median; min)
32 (17–40) 23 (17–31) 40 (24–71) 0.050
Cardiac  rhythm (%)
VF/VT  46 (90.2) 36 (90.0) 10 (90.9) 1.000
PEA/asystole 5 (9.8) 4  (10.0) 1 (9.1)
Basic  disease (%)
Ischemia  37 (72.5) 26 (65.0) 11 (100) 0.023
Others 14 (26.5) 14 (35.0) 0 (0)
Vital  sign after ROSC
SBP  (mmHg) 136 ± 45 139 ± 45 120 ± 47 0.218
DBP (mmHg) 68 ± 36 73 ± 33 50 ± 41 0.110
HR (bpm) 97 ± 33 97 ± 29 93 ± 44 0.685
LVEF (%) 42.6 ± 18.6 44.4 ± 17.9 35.7 ± 20.6 0.174
Mean ± standard deviation in age, SBP, DBP, HR and LVEF, median (interquartile
range)  in time, and number of cases (%) in others. CKD, chronic kidney disease;
CPR,  cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; VF,
ventricular ﬁbrillation; VT, ventricular tachycardia; PEA, pulseless electrical activity;8 T. Shinada et al. / Journal
nd required a blood transfusion, the bleeding was  deﬁned as a
omplication.
Complications associated with the cardiovascular system,
ncluding arrhythmia and blood pressure ﬂuctuation during TH
ere also assessed in this study.
eurological outcomes
The  neurological outcomes were evaluated using the cerebral
erformance category (CPC) 30 days after cardiac arrest (CPC-1,
ood cerebral performance; CPC-2, moderate cerebral disability;
PC-3, severe cerebral disability; CPC-4, coma, vegetative state;
PC-5, death) [7].
tatistical  analysis
The  patients were divided into two groups based on the use of
he Arctic Sun 2000® or conventional standard cooling blankets
or TH, and the clinical features during TH and the neurological
utcomes were compared between the two groups.
All continuous data are expressed as the mean ± standard
eviation or median and 25–75% interquartile range. The mean dif-
erences between groups were analyzed using Student’s t-test or
he Mann–Whitney U test. Proportional differences were analyzed
sing the Pearson chi-square test or Fisher’s exact test. A p-value
f <0.05 was considered to be statistically signiﬁcant. All data were
nalyzed using the SPSS Statistics version 20 software program for
indows (IBM SPSS Statistics, Chicago, IL, USA).
esults
ackgrounds of the patients
Of  the 130 patients, 51 who did not regain consciousness after
OSC following cardiac arrest and were treated with TH using sur-
ace cooling were enrolled in this study (Fig. 2). Forty patients were
ooled using the Arctic Sun 2000®, and 11 patients were cooled
sing conventional standard cooling blankets. The clinical charac-
eristics of the two treatment groups are shown in Table 1. The
aseline characteristics of the patients and cardiac arrest episodes
ere not signiﬁcantly different between the two treatment groups,
ig. 2. Flow chart of the patients who received therapeutic hypothermia using the
rctic Sun 2000® or conventional cooling blankets. ROSC, return of spontaneous
irculation.SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left
ventricular ejection fraction.
except for basic heart disease. The interval from the onset to ROSC
in the conventional standard cooling blankets group was  relatively
longer compared with the Arctic Sun 2000® group, but the differ-
ence was  not statistically signiﬁcant (p = 0.050).
Methods of performing therapeutic hypothermia
TH was initiated using a combination of cooling methods in
the ER or ICU to achieve a body temperature of 34 ◦C. Infusion of
ice-cold ﬂuid and/or gastric lavage with ice-cold water was used
together with surface cooling to induce TH in some cases (Table 2).
All patients treated with gastric lavage using ice-cold water for
additional cooling were cooled with an infusion of ice-cold ﬂuids.
Fifteen patients (13 patients treated with the Arctic Sun 2000® and
2 patients treated with blankets) were cooled using only surface
cooling.
The clinical courses of the patients during TH are shown
in Table 2. The interval of onset to the target body tempera-
ture and the start of TH to the target body temperature were
signiﬁcantly shorter in the patients treated with the Arctic
Sun 2000® than in those treated with standard cooling blan-
kets.
Body temperature during therapeutic hypothermia
There were no differences between the two  groups in body
temperature before TH; however, the minimal body temperature
during TH was  signiﬁcantly lower in the patients treated with
standard cooling blankets than in those treated with the Arctic Sun
2000® (Fig. 3).
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Table  2
Additional cooling method and clinical course of therapeutic hypothermia.
Arctic Sun® (n = 40) Blanket (n = 11) p-value
Infusion of ice-cold ﬂuids (%) 27 (67.5) 9 (81.8) 0.472
Gastric  lavage with ice-cold water and infusion of ice-cold ﬂuids (%) 4  (10.0) 6 (54.5) 0.004
No  other cooling methods (%) (only Arctic Sun or cooling blanket) 13 (32.5) 2 (18.2) 0.472
Onset  to target BT (min) 382 (255–510) 594 (420–782) 0.002
ROSC  to target BT (min) 355 (235–479) 566 (388–777) 0.067
Start  of TH to target BT (min) 234 (128–365) 375 (324–534) 0.019
Duration  of TH (min) 1537 (1375–1763) 1770 (1160–1954) 0.423
Number of cases (%), and median (interquartile range) in time. BT, body temperature; ROSC, return of spontaneous circulation; TH, therapeutic hypothermia.















dig. 3. Body temperature (BT) before therapeutic hypothermia (TH) and the minimal
se of intravenous catecholamines and mechanical support
uring  therapeutic hypothermia
The  use of intravenous catecholamines and mechanical support
uring TH in the two groups is shown in Table 3. The rates of cat-
cholamine administration and mechanical support (IABP, PCPS,
HDF) were not signiﬁcantly different between the two  groups.
he maximum infusion doses of dopamine and noradrenaline dur-
ng TH were not signiﬁcantly different between the two groups;
owever, the infusion dose of dobutamine during TH was signiﬁ-
antly lower in the patients treated with Arctic Sun 2000® than in
hose treated with standard cooling blankets (Fig. 4).
able 3
se  of intravenous catecholamine and mechanical support during therapeutic
ypothermia.
Arctic Sun® (n = 40) Blanket (n = 11) p-value
Catecholamine use (%)
Dopamine  9 (22.5) 4 (36.4) 0.439
Dobutamine 6 (15.0) 3 (27.3) 0.385
Noradrenaline 9 (22.5) 3 (27.3) 0.706
Mechanical support (%)
IABP  13 (32.5) 4 (36.4) 1.000
PCPS 7 (17.5) 3 (27.3) 0.669
CHDF 10 (25.0) 5 (45.5) 0.264
umber of cases (%). IABP, intra-aortic balloon pumping; PCPS, percutaneous car-
iopulmonary support; CHDF, continuous hemodiaﬁltration.temperature (BT) during therapeutic hypothermia (TH). Mean ± standard deviation.
Complications and neurological outcomes
There were no differences in the incidence of complications
during TH, including pneumonia and bleeding between the two
groups (Table 4). Bradycardia requiring transvenous temporary
pacing occurred in only one patient in the Arctic Sun 2000® group;
however, this case was  administered a -blocker to prevent VF/VT
during TH.
The  CPC at 30 days after cardiac arrest was not signiﬁcantly
different between the two groups (Table 4).
Discussion
Cardiogenic cardiac arrest is caused by ischemic heart disease,
idiopathic cardiomyopathy, and various other causes. In addi-
tion, the importance of prominent J waves in patients presenting
with VF without structural heart disease was  recently reported
[8].
Regardless of the cause of cardiac arrest, the post-cardiac arrest
care is important to improve the neurological outcome of the
patients [1]. Many studies have been performed to identify ways to
improve the prognosis of cardiac arrest patients. Until now, no drug
was proved to improve the prognosis of cardiac arrest patients. In a
recent study, the administration of intravenous adrenaline before
arrival at the hospital in out-of-hospital cardiac arrest patients
did not improve their prognosis [9]. In our study, 23 patients
were administered adrenaline for resuscitation in-hospital or






















NFig. 4. Maximum dose of catecholamines during
ut-of-hospital, and it did not contribute to a good neurological
utcome in any of the study patients.
A low systolic blood pressure was reported to be associated
ith a poor in-hospital outcome in patients with acute myocar-
ial infarction [10]. In our study, the systolic blood pressure after
he ROSC was not lower than that in that report, and did not differ
igniﬁcantly between the groups (Table 1).
After two randomized clinical trials were published [2,3], TH
ecame the standard method of providing post-cardiac care. So far,
H is the only method that has proven to be useful for improving the
eurological outcome of cardiac arrest patients. There are a num-
er of methods to induce hypothermia. Infusion of ice-cold ﬂuids is
ffective and safe for initiating cooling; however, it must be com-
ined with other methods to maintain hypothermia [11]. In order
o maintain hypothermia, the use of standard cooling blankets and
he frequent application of ice bags are readily available and effec-
ive methods. In addition to these methods, feedback-controlled
ndovascular catheters and surface cooling devices are available.
ndovascular cooling systems are effective for TH [12]; however,
able 4
omplications during therapeutic hypothermia and neurological status on 30th hos-
ital day.






Pneumonia  12 (23.5) 11 (27.5) 1 (9.1) 0.422
Bleeding 3 (5.9) 1 (2.5) 2 (18.2) 0.114
CPC at 30th hospital days (%)
CPC-1 31 (60.8) 25 (62.5) 6 (54.5) 0.465
CPC-2 4 (7.8) 4 (10.0) 0 (0)
CPC-3 1 (2.0) 1  (2.5) 0 (0)
CPC-4 4 (7.8) 2 (5.0) 2 (18.2)
CPC-5 11 (21.6) 8 (20.0) 3 (27.3)
CPC 1 or 2 35 (68.6) 29 (72.5) 6 (54.5) 0.288
CPC 3 or 4 or 5 16 (31.4) 11 (27.5) 5 (45.5)
umber of cases (%). CPC, cerebral performance category.peutic hypothermia. Mean ± standard deviation.
they are invasive due to the need to insert a cooling catheter into
the vena cava, which carries a risk of infection and thrombosis. The
Arctic Sun 2000® is a safe and effective surface cooling device used
to initiate and maintain hypothermia that employs adherent gel
pads and a precise feedback-controlled system [13]. In this study,
we investigated the clinical efﬁcacy of the Arctic Sun 2000® for TH
maintenance compared to conventional standard cooling blankets.
The ideal timing of TH is still unclear [1]. There have been several
reports about the relationship between the time it takes to achieve
the target body temperature and the neurological outcome. Some
previous studies reported that there was a relationship between
the early achievement of the target body temperature and a good
neurological outcome [14,15]. However, other studies reported that
early achievement of the target body temperature was related to
a poor neurological outcome and prognosis [16,17]. The Arctic Sun
2000® is reported to cool patients to a temperature of 34 ◦C more
rapidly than standard cooling blankets; however, in one study, the
CPC at 90 days did not differ between two groups [18]. In addition, in
our study, the Arctic Sun 2000® cooled the comatose patients more
rapidly than standard cooling blankets and the CPC at 30 days did
not differ between the two  groups.
PCPS can induce TH rapidly by precisely controlling the body
temperature [19]. We  performed PCPS and IABP if the patients were
hemodynamically unstable. We terminated PCPS and removed the
arterial and venous cannulas for PCPS as soon as possible after
the patients became stable after starting TH in order to prevent
the development of complications related to PCPS (e.g. infection,
thromboembolism, lower limb ischemia). We  used surface cooling
devices for all patients with PCPS from the beginning of TH in order
to simplify the management of the body temperature (maintenance
and rewarming) after terminating the PCPS during TH.
In  this study, the Arctic Sun 2000® was used to safely perform
TH and precisely maintain the target body temperature during TH.
There were no differences between the two  groups in body temper-
ature before TH; however, the minimal body temperature during
TH was signiﬁcantly lower in the patients treated with conventional
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un 2000®. The Arctic Sun 2000® precisely maintained the target
ody temperature during TH due to its automatic body temperature
eedback-control mechanism and the use of conductive, adherent
el pads. Therefore, the ICU staff did not need to be nervous about
aintaining the target body temperature of the comatose patients
fter cardiac arrest.
The  complications associated with the cardiovascular system
hat occur during TH include bradycardia and an increase in blood
ressure [20]. A risk of clinically signiﬁcant arrhythmias occurs only
f the core temperature decreases below 30 ◦C. In this study, brady-
ardia requiring transvenous temporary pacing occurred in only
ne case; however, this case was administered a -blocker to pre-
ent VT/VF during TH. Therefore, the bradycardia in this case may
ave been due to the combination of the TH and -blocking agent.
omplications associated with an increase in blood pressure did
ot occur in any of our patients.
The LVEF before TH did not differ between the two  groups; how-
ver, the maximum infusion dose of dobutamine during TH was
igniﬁcantly lower in the patients treated with the Arctic Sun 2000®
han in those treated with standard cooling blankets. Hypother-
ia does not impair the cardiac systolic function, although it does
mpair the left ventricular diastolic function. Worsening of diastolic
ysfunction is highly correlated with a decreasing body temper-
ture [21]. In addition, systemic vascular resistance is increased
uring hypothermia [20,21]. Increased systemic vascular resistance
nd an impaired left ventricular diastolic function during TH may
ause heart failure with subsequent pulmonary congestion. Dobut-
mine is used to treat heart failure by improving the cardiac index.
n addition, dobutamine reduces the left ventricular diastolic ﬁll-
ng pressure, pulmonary capillary wedge pressure, and systemic
ascular resistance [22,23]. Patients treated with standard cool-
ng blankets during TH may  easily suffer from heart failure due
o increasing systemic vascular resistance and an impaired dia-
tolic function, as a result of the lower temperature observed during
H compared to patients treated with the Arctic Sun 2000®. Fur-
hermore, there is a possibility that more dobutamine is required
o improve heart failure in patients treated with standard cool-
ng blankets than in patients treated with the Arctic Sun 2000®
ue to decreases in the left ventricular diastolic ﬁlling pressure,
ulmonary capillary wedge pressure, and systemic vascular resis-
ance.
tudy limitations
First,  this study included a small number of patients with car-
iogenic cardiac arrest and was retrospectively conducted at only
ne university hospital. Second, the decision to administer cate-
holamines and the selection of the infusion dose of these drugs
as made by the ICU physician based on the patient’s urinary vol-
me, pulmonary congestion on chest X-ray, oxygenation, lactate
evel, and central venous pressure, not on the pulmonary capillary
edge pressure or cardiac index. Third, there is another possibility
o affect maximum infusion dose of dobutamine. The interval from
he onset to the ROSC in the standard cooling blankets group was
elatively long, and there were more patients with ischemic heart
isease in the standard cooling blankets group compared with the
rctic Sun 2000® group, so these differences might have affected
he cardiac diastolic function and systemic vascular resistance after
he ROSC. The LVEF after the ROSC was not signiﬁcantly different
etween the two groups; however, these factors (onset to ROSC and
asic disease) may  still have affected the maximum infusion dose
f dobutamine during TH.
Prospective, large, multicenter cohort studies are recommended
o clarify the difference between patients treated with and without
he Arctic Sun 2000®.
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Conclusions
Performing TH following cardiac arrest using the Arctic Sun
2000® is safe and effective for precisely maintaining the target
body temperature, and can be used to reduce the infusion dose
of dobutamine to treat heart failure during TH.
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